» Articles » PMID: 21149712

CBP Gene Transfer Increases BDNF Levels and Ameliorates Learning and Memory Deficits in a Mouse Model of Alzheimer's Disease

Overview
Specialty Science
Date 2010 Dec 15
PMID 21149712
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

Cognitive dysfunction and memory loss are common features of Alzheimer's disease (AD). Abnormalities in the expression profile of immediate early genes that play a critical role in memory formation, such as the cAMP-response element binding protein (CREB), have been reported in the brains of AD patients. Here we show that amyloid-β (Aβ) accumulation, which plays a primary role in the cognitive deficits of AD, interferes with CREB activity. We further show that restoring CREB function via brain viral delivery of the CREB-binding protein (CBP) improves learning and memory deficits in an animal model of AD. Notably, such improvements occur without changes in Aβ and tau pathology, and instead are linked to an increased level of brain-derived neurotrophic factor. The resulting data suggest that Aβ-induced learning and memory deficits are mediated by alterations in CREB function, based on the finding that restoring CREB activity by directly modulating CBP levels in the brains of adult mice is sufficient to ameliorate learning and memory. Therefore, increasing CBP expression in adult brains may be a valid therapeutic approach not only for AD, but also for various brain disorders characterized by alterations in immediate early genes, further supporting the concept that viral vector delivery may be a viable therapeutic approach in neurodegenerative diseases.

Citing Articles

High-intensity training on CREB activation for improving brain health: a narrative review of possible molecular talks.

Li P, Hu Y, Tong L, Bi X Front Endocrinol (Lausanne). 2025; 15:1498495.

PMID: 39902166 PMC: 11788139. DOI: 10.3389/fendo.2024.1498495.


DNA methylation, histone acetylation in the regulation of memory and its modulation during aging.

Singh P, Paramanik V Front Aging. 2025; 5():1480932.

PMID: 39835300 PMC: 11743476. DOI: 10.3389/fragi.2024.1480932.


Epigenetic Explorations of Neurological Disorders, the Identification Methods, and Therapeutic Avenues.

Firdaus Z, Li X Int J Mol Sci. 2024; 25(21).

PMID: 39519209 PMC: 11546397. DOI: 10.3390/ijms252111658.


PROTACs Targeting Epigenetic Proteins.

Zhang C, He Y, Sun X, Wei W, Liu Y, Rao Y Acta Mater Med. 2024; 2(4):409-429.

PMID: 39221114 PMC: 11364368. DOI: 10.15212/amm-2023-0039.


Epigenetic Changes in Alzheimer's Disease: DNA Methylation and Histone Modification.

De Plano L, Saitta A, Oddo S, Caccamo A Cells. 2024; 13(8.

PMID: 38667333 PMC: 11049073. DOI: 10.3390/cells13080719.


References
1.
Wang X, Blanchard J, Kohlbrenner E, Clement N, Linden R, Radu A . The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J. 2010; 24(11):4420-32. PMC: 3229424. DOI: 10.1096/fj.10-158477. View

2.
Neeper S, Gomez-Pinilla F, Choi J, Cotman C . Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res. 1996; 726(1-2):49-56. View

3.
Fahnestock M, Marchese M, Head E, Pop V, Michalski B, Milgram W . BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol Aging. 2010; 33(3):546-54. PMC: 2935515. DOI: 10.1016/j.neurobiolaging.2010.03.019. View

4.
Cleary J, Walsh D, Hofmeister J, Shankar G, Kuskowski M, Selkoe D . Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2004; 8(1):79-84. DOI: 10.1038/nn1372. View

5.
Peng S, Garzon D, Marchese M, Klein W, Ginsberg S, Francis B . Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci. 2009; 29(29):9321-9. PMC: 3411546. DOI: 10.1523/JNEUROSCI.4736-08.2009. View